CSCI
Income statement / Annual
Last year (2024), COSCIENS Biopharma Inc.'s total revenue was $9.13 M,
an increase of 27.77% from the previous year.
In 2024, COSCIENS Biopharma Inc.'s net income was -$15.31 M.
See COSCIENS Biopharma Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$9.13 M |
$7.14 M |
$14.57 M |
$13.49 M |
$11.86 M |
$9.86 M |
$8.51 M |
$10.28 M |
$10.17 M |
$7.69 M |
| Cost of Revenue |
$4.86 M
|
$4.21 M
|
$6.02 M
|
$5.28 M
|
$5.88 M
|
$5.69 M
|
$4.00 M
|
$4.50 M
|
$3.21 M
|
$2.62 M
|
| Gross Profit |
$4.73 M
|
$2.94 M
|
$8.56 M
|
$8.21 M
|
$5.98 M
|
$4.17 M
|
$4.51 M
|
$5.78 M
|
$6.96 M
|
$5.06 M
|
| Gross Profit Ratio |
0.52
|
0.41
|
0.59
|
0.61
|
0.5
|
0.42
|
0.53
|
0.56
|
0.68
|
0.66
|
| Research and Development Expenses |
$8.30 M
|
$2.04 M
|
$1.37 M
|
$3.04 M
|
$1.48 M
|
$1.83 M
|
$1.96 M
|
$1.28 M
|
$683,818.00
|
$450,542.00
|
| General & Administrative Expenses |
$0.00
|
$5.59 M
|
$2.73 M
|
$2.54 M
|
$2.57 M
|
$2.26 M
|
$2.20 M
|
$2.26 M
|
$1.63 M
|
$1.82 M
|
| Selling & Marketing Expenses |
$0.00
|
$30,517.00
|
$21,778.00
|
$36,955.00
|
$87,082.00
|
$325,529.00
|
$165,597.00
|
$25,531.00
|
$3,220.00
|
$5,494.02
|
| Selling, General & Administrative Expenses |
$10.45 M
|
$5.53 M
|
$2.87 M
|
$2.58 M
|
$2.66 M
|
$2.59 M
|
$2.37 M
|
$2.28 M
|
$1.63 M
|
$1.82 M
|
| Other Expenses |
$4.26 M
|
$0.00
|
$0.00
|
$162,264.00
|
$181,366.00
|
$199,563.00
|
$87,169.00
|
$108,596.00
|
$180,687.00
|
$177,695.00
|
| Operating Expenses |
$23.01 M
|
$7.57 M
|
$4.24 M
|
$5.78 M
|
$4.32 M
|
$4.62 M
|
$4.41 M
|
$3.67 M
|
$2.49 M
|
$2.45 M
|
| Cost And Expenses |
$27.87 M
|
$11.77 M
|
$10.25 M
|
$11.06 M
|
$10.20 M
|
$10.31 M
|
$8.42 M
|
$8.17 M
|
$5.71 M
|
$5.07 M
|
| Interest Income |
$441,000.00
|
$59,000.00
|
$145,000.00
|
$0.00
|
$0.00
|
$0.00
|
$263,822.00
|
$77,697.00
|
$148,196.00
|
$131,704.00
|
| Interest Expense |
$129,000.00
|
$136,000.00
|
$143,000.00
|
$119,128.00
|
$137,365.00
|
$154,253.00
|
$35,275.00
|
$50,979.00
|
$27,962.00
|
$38,032.00
|
| Depreciation & Amortization |
$1.61 M
|
$1.44 M
|
$1.47 M
|
$1.48 M
|
$1.44 M
|
$322,323.00
|
$56,940.00
|
$259,327.00
|
$267,429.00
|
$282,712.00
|
| EBITDA |
-$13.49 M |
-$2.84 M |
$6.14 M |
$4.18 M |
$3.04 M |
$686,844.00 |
-$216,278.64 |
-$29,110.14 |
$4.29 M |
$3.08 M |
| EBITDA Ratio |
-1.48
|
-0.4
|
0.42
|
0.31
|
0.26
|
0.07
|
-0.03
|
-0
|
0.42
|
0.4
|
| Operating Income Ratio |
-2
|
-0.65
|
0.3
|
0.18
|
0.14
|
-0.05
|
0.01
|
0.21
|
0.44
|
0.34
|
| Total Other Income/Expenses Net |
$3.06 M
|
$259,000.00
|
$208,000.00
|
$158,649.00
|
-$203,295.27
|
-$420,570.79
|
-$770,397.86
|
-$2.45 M
|
-$473,218.51
|
$146,988.00
|
| Income Before Tax |
-$15.23 M
|
-$4.37 M
|
$4.53 M
|
$2.59 M
|
$1.46 M
|
-$869,679.32
|
-$676,363.22
|
-$339,417.10
|
$3.99 M
|
$2.76 M
|
| Income Before Tax Ratio |
-1.67
|
-0.61
|
0.31
|
0.19
|
0.12
|
-0.09
|
-0.08
|
-0.03
|
0.39
|
0.36
|
| Income Tax Expense |
$84,000.00
|
-$885,000.00
|
$1.08 M
|
-$52,919.17
|
$415,866.00
|
-$2,608.96
|
-$444,696.52
|
$422,630.00
|
$1.30 M
|
-$784,125.42
|
| Net Income |
-$15.31 M
|
-$3.49 M
|
$3.45 M
|
$2.64 M
|
$1.46 M
|
-$867,070.36
|
-$231,666.70
|
-$762,047.71
|
$2.69 M
|
$3.55 M
|
| Net Income Ratio |
-1.68
|
-0.49
|
0.24
|
0.2
|
0.12
|
-0.09
|
-0.03
|
-0.07
|
0.26
|
0.46
|
| EPS |
-5.93 |
-1.89 |
2.51 |
1.69 |
0.85 |
-0.48 |
-0.13 |
-0.43 |
2.13 |
3.38 |
| EPS Diluted |
-5.93 |
-1.89 |
2.5 |
1.69 |
0.85 |
-0.48 |
-0.13 |
-0.43 |
2.13 |
3.38 |
| Weighted Average Shares Out |
$2.58 M
|
$1.85 M
|
$1.84 M
|
$1.83 M
|
$1.83 M
|
$1.82 M
|
$1.80 M
|
$1.78 M
|
$1.60 M
|
$1.46 M
|
| Weighted Average Shares Out Diluted |
$2.58 M
|
$1.85 M
|
$1.85 M
|
$1.85 M
|
$1.84 M
|
$1.82 M
|
$1.80 M
|
$1.78 M
|
$1.68 M
|
$1.54 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
